Loading…
Revelation Biosciences, Inc. is projected to rise to $1.24 by 2027, a +24% move from its current price of $1.00. REVB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9677 | $1.00 | $1.04 | +0.08% |
| Jul 14 | $0.9551 | $1.00 | $1.05 | +0.16% |
| Jul 15 | $0.9457 | $1.00 | $1.06 | +0.24% |
| Jul 16 | $0.938 | $1.00 | $1.07 | +0.33% |
| Jul 17 | $0.9313 | $1.00 | $1.08 | +0.41% |
| Jul 18 | $0.9254 | $1.00 | $1.09 | +0.49% |
| Jul 19 | $0.92 | $1.01 | $1.10 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.92 | $1.01 | $1.10 | +0.57% |
| Week 2 | $0.8918 | $1.01 | $1.15 | +1.14% |
| Week 3 | $0.8719 | $1.02 | $1.19 | +1.72% |
| Week 4 | $0.8562 | $1.02 | $1.22 | +2.30% |
| Week 5 | $0.8431 | $1.03 | $1.26 | +2.88% |
| Week 6 | $0.832 | $1.03 | $1.29 | +3.47% |
| Week 7 | $0.8222 | $1.04 | $1.32 | +4.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation to optimize health. Its lead product candidate is Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that modulates and rebalances a dysregulated inflammatory response.
The company also engages in the prevention and treatment of disease by developing therapeutics that modulate the innate immune system, including GEM-AKI for acute kidney injury and GEM-CKD for chronic kidney disease. Revelation Biosciences, Inc. was formerly known as Petra Acquisition, Inc.
and changed its name in January 2022. The company was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc. (REVB) is the asset with a current price of $1.04 and a market capitalization of $4.06M, ranking 5084. The current price outlook is informed by a range of forecast values across years, starting with 2026 and extending through 2050.
The 2026 forecast shows a min of $0.96, an avg of $1.04, and a max of $1.67, with a neutral sentiment and 0% ROI. The forecast progresses through 2027–2029 with bullish sentiment and rising averages, including 2027 (avg $1.30, max $1.82, ROI 25.1%), 2028 (avg $1.32, max $1.94, ROI 26.9%), and 2029 (avg $1.33, max $2.03, ROI 28.2%). In 2030 the min is $0.8411, the avg is $1.22, the max is $1.92, with a 17.5% ROI and neutral sentiment.
The outlook continues with 2033–2035 showing stronger gains and bullish sentiment (2033 avg $1.42, max $2.41; 2034 avg $1.74, max $3.01; 2035 avg $1.73, max $3.06). By 2040, the forecast reaches an avg of $1.86 and a max of $3.54 with a 78.6% ROI and bullish sentiment, and by 2050 an avg of $3.82 and a max of $8.13 with a 267.4% ROI and bullish sentiment.
A major floor 12.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 10.0% above — a clean break opens room to run.
A major ceiling 35.0% above — clearing it would confirm fresh momentum.
Key REVB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REVB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9906 | Buy | $0.9958 | Buy |
| MA 10 | $1.01 | Sell | $1.00 | Sell |
| MA 20 | $1.01 | Sell | $1.01 | Sell |
| MA 50 | $1.04 | Sell | $1.08 | Sell |
| MA 100 | $1.14 | Sell | $1.69 | Sell |
| MA 200 | $2.53 | Sell | $59.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.24 | Neutral |
| Stoch RSI (14) | 42.12 | Neutral |
| CCI (20) | -23.72 | Neutral |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -4.76 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 45.48 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 0.96 | Buy |
| ADX (14) | 10.11 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is neutral, with RSI at 50. The message from momentum is balanced, not overbought or oversold. The 50-day simple moving average sits at $1.06, versus a 200-day moving average at $2.76, illustrating a mixed near-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.96 | $1.00 | $1.51 | 0% | Neutral | |
| $0.9674 | $1.24 | $1.70 | +24% | Bullish | |
| $0.9327 | $1.24 | $1.77 | +24% | Bullish | |
| $0.9004 | $1.23 | $1.82 | +23% | Bullish | |
| $0.8452 | $1.19 | $1.81 | +19% | Neutral | |
| $0.8173 | $1.18 | $1.84 | +18% | Neutral | |
| $0.7796 | $1.15 | $1.83 | +15% | Neutral | |
| $0.9045 | $1.36 | $2.22 | +36% | Bullish | |
| $1.04 | $1.60 | $2.65 | +60% | Bullish | |
| $1.03 | $1.62 | $2.73 | +62% | Bullish | |
| $1.02 | $1.74 | $3.16 | +74% | Bullish | |
| $1.76 | $3.54 | $7.10 | +254% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.96 | $1.00 | $1.18 | +0.00% |
| August 2026 | $0.8562 | $1.02 | $1.24 | +1.68% |
| September 2026 | $0.8988 | $1.08 | $1.34 | +5.90% |
| October 2026 | $0.8984 | $1.08 | $1.36 | +0.70% |
| November 2026 | $0.909 | $1.10 | $1.40 | +1.83% |
| December 2026 | $0.9663 | $1.18 | $1.51 | +6.94% |
Click any year to see its month-by-month REVB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The REVB price prediction for 2026 points to an average of $1.00 (low $0.96, high $1.51) — a potential gain of 0% on today's $1.00. Price action looks broadly range-bound.
In 2027, REVB is projected to trade between $0.9674 and $1.70, averaging $1.24 — a potential gain of +24% from today's $1.00. That is up +24% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Revelation Biosciences, Inc.'s 2028 outlook centres on $1.24, within a $0.9327 to $1.77 range. That is 0% versus the projected 2027 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2029, REVB could reach as high as $1.82, with a base case around $1.23 and support toward $0.9004 — roughly +23% from $1.00. Buyers look set to stay in control over this stretch.
Expect REVB to range from $0.8452 to $1.81 through 2030. The $1.19 average target implies a +19% move from current prices. That is -4% versus the projected 2029 average. Price action looks broadly range-bound.
The REVB price prediction for 2031 points to an average of $1.18 (low $0.8173, high $1.84) — a potential gain of +18% on today's $1.00. A consolidation phase looks the most probable path here.
In 2032, REVB is projected to trade between $0.7796 and $1.83, averaging $1.15 — a potential gain of +15% from today's $1.00. That is -2% versus the projected 2031 average. Price action looks broadly range-bound.
Revelation Biosciences, Inc.'s 2033 outlook centres on $1.36, within a $0.9045 to $2.22 range. That is up +19% on the projected 2032 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, REVB could reach as high as $2.65, with a base case around $1.60 and support toward $1.04 — roughly +60% from $1.00. Momentum favours further upside here.
Expect REVB to range from $1.03 to $2.73 through 2035. The $1.62 average target implies a +62% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The REVB price prediction for 2040 points to an average of $1.74 (low $1.02, high $3.16) — a potential gain of +74% on today's $1.00. Momentum favours further upside here.
In 2050, REVB is projected to trade between $1.76 and $7.10, averaging $3.54 — a potential gain of +254% from today's $1.00. That is up +103% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in REVB today (≈ 1,000 REVB) could be worth
$3,536.86
+$2,536.86 (+254%) by 2050 · US Dollar
Based on the average projected REVB price of $3.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REVBwould be worth at today's price.
$1,000 invested in REVB on Jul 10, 2025 (≈ 88.495574 REVB) would be worth
$88.5
-$911.5 (-91.2%) today · 0.09× · US Dollar
Based on a REVB entry price of $11.3 vs. today's $1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.08 | $925.93 | -7.4% |
| 1 month ago | $1.03 | $970.87 | -2.9% |
| 3 months ago | $1.17 | $854.7 | -14.5% |
| 6 months ago | $3.6 | $277.78 | -72.2% |
| 1 year ago | $11.3 | $88.5 | -91.2% |
| All time (5.0y) ago | $2,022,048 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REVB forecast.
Our base-case forecast reaches $2.00 around 2050.
Implied market cap at $2.00: $7.82M
The multi-year forecast shows a path from neutral in 2026 toward stronger upside in later years, with a shift to bullish sentiment in several years and a general rise in the average price. The 2030 forecast places the avg at $1.22 with a 17.5% ROI and neutral sentiment, followed by a continued bullish arc through 2040 (avg $1.86, ROI 78.6) and 2050 (avg $3.82, ROI 267.4). These figures imply meaningful upside potential over the longer horizon, but they are estimates, not guarantees.
Investors should consider that sentiment and returns vary by year and are subject to market risk.
Tap a question to reveal the answer.
Avg $1.22, min $0.8411, max $1.92, ROI 17.5, sentiment NEUTRAL.
Forecasts show neutral in 2026, turning bullish in 2027–2029 and continuing bullish in later years, with 2030 avg $1.22 (ROI 17.5), 2040 avg $1.86 (ROI 78.6), and 2050 avg $3.82 (ROI 267.4). These are estimates, not guarantees.
Yes, the 2050 max forecast is $8.13, with the 2050 avg $3.82 and bullish sentiment; other years show max values above $2.00, indicating potential upside within the given forecast.
Current price $1.04; market capitalization $4.06M.
Low $0.8075, High $1.34.
Revelation Biosciences, Inc. Community Discussion
0Share your Revelation Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.